Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Senate Begins Debate On Sotomayor's Supreme Court Confirmation
The Senate on Tuesday began its floor debate on the confirmation of Supreme Court nominee Sonia Sotomayor, the Wall Street Journal reports (Bravin, Wall Street Journal, 8/4). The debate will continue for the rest of the week before a final floor vote is held Thursday or Friday (Oliphant/Savage, Los Angeles Times, 8/5). Twenty-eight Republicans have said they will oppose her nomination. As of Tuesday, six Republicans were undecided (Stern, CQ Today, 8/4). In addition, at least six Republicans plan to vote for Sotomayor"s confirmation, while none of the 60 Democrats in the Senate have come out against her.Senate Judiciary Committee ranking member Jeff Sessions (R-Ala.), who has announced his opposition, said, "I have expressed the view since this process began that we are at a fork in the road," asking, "Will we continue to adhere to the classical idea of American jurisprudence? Or will we follow results-oriented judging in which judges cease to be committed to equal justice?" He also said that "certain aspects of her record troubled me, ... whether she is deeply committed to the ideal of objectivity and impartiality" (Los Angeles Times, 8/5). Sotomayor opponent Sen. James Inhofe (R-Okla.) expressed concern about Sotomayor"s statement in a speech that "a wise Latina woman with the richness of her experience would more often than not reach a better conclusion" than a white male judge. Inhofe said, "Well, that"s pretty emphatic. There"s no other way you can interpret that," adding, "She thinks a woman with her experience can make a better conclusion than a white male," and "to me, I consider that racist" (CQ Today, 8/4).However, Sotomayor supporter Sen. Patrick Leahy (D-Vt.) said, "Those who struggle to pin the label of judicial activist on Judge Sotomayor are met by her solid record of judging based on the law." He added, "She is a restrained, experienced and thoughtful judge who has shown no biases in her rulings." Sen. Dianne Feinstein (D-Calif.) said, "You can"t find a nominee with better experience than Judge Sotomayor. She has seen the law from all sides." Sen. Robert Menendez (D-N.J.) said, "When Judge Sotomayor takes her seat at the Supreme Court, America will have come of age" (Los Angeles Times, 8/4).
diet pills
Spine-shaped Gold Protrusions Improve The Adherence And Electrical Coupling Of Neurons With The Surface Of Micro-electronic Devices
Interfacing neurons with micro- and nano-electronic devices has been a subject of intense studies over the last decade and is used both in basic research and medical applications. The electronic devices used in such neuroelectronic hybrids are mainly planar metal electrodes and planar transistors.
News of the day
New York City Labor Unions Agree To Reductions In Health Benefits
"Mayor Michael R. Bloomberg and city labor officials announced a tentative agreement Tuesday to amend health benefits for more than 550,000 current and retired city employees, guaranteeing the city $400 million in savings over the next two fiscal years," The New York Times reports. The arrangement imposes "$50 to $100 co-payments for about one-fifth of current and retired city employees, and eliminates coverage for preventive dental care at certain offices." The paper adds, "For most other city employees, the plan would restrict certain hospital, ambulatory and hemodialysis coverage to network providers and would implement several other administrative cost-saving measures." The agreement requires union approval.
Cardiovascular

Statement By Merck & Co., Inc. Regarding FOSAMAX® (alendronate Sodium) And Rare Cases Of Osteonecrosis Of The Jaw

Merck is committed to putting patients first and providing accurate information regarding the efficacy, safety and tolerability of our medicines. Merck offers the following statement concerning the osteoporosis medication FOSAMAX® (alendronate sodium) and reports of jaw problems associated with delayed healing and infection of the jaw often following tooth extraction. The condition is known as osteonecrosis of the jaw (ONJ). ONJ is not well understood and may occur for a number of reasons. Most reported cases of bisphosphonate-associated osteonecrosis have been in cancer patients treated with intravenous bisphosphonates, but cases have occurred in patients with postmenopausal osteoporosis and other diagnoses. Known risk factors for osteonecrosis include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), poor oral hygiene, and co-morbid disorders (e.g., pre-existing dental disease, anemia, coagulopathy, infection). In controlled clinical trials involving more than 28,000 patients (over 17,000 of whom were treated with FOSAMAX), contributing as much as 10 years" data with alendronate, there have been no reports of ONJ. This includes ~3000 osteoporosis patients taking alendronate for 3-5 years and ~800 patients taking alendronate for 8-10 years. Since their market introduction, over 225 million total prescriptions have been dispensed for FOSAMAX/FOSAMAX Plus D, Actonel (risedronate) and Boniva (ibandronate) in the U.S. In worldwide post-marketing experience with FOSAMAX/FOSAMAX Plus D, rare reports consistent with osteonecrosis of the jaw have been received. Many of these reports lack sufficient clinical details to make definitive assessments and/or are confounded, particularly since a generally accepted definition of ONJ in the general population is unknown. As of January 15, 2009, Merck estimates the worldwide, cumulative reporting rate of osteonecrosis of the jaw to range between 1.6/100,000 patient-treatment-years and 3.84/100,000 patient-treatment-years, regardless of causality. On January 31, 2005, Merck received a request dated January 24, 2005 from the Food and Drug Administration to update the label for FOSAMAX to include bisphosphonate class labeling for ONJ. Merck submitted a draft revised label to FDA on March 1, 2005. FDA comments on this draft revised label were received in June 2005, and the new label was made publicly available in July 2005. Rare cases of ONJ have also been reported in patients who do not have osteoporosis and who have not taken any bisphosphonate medicines. These cases have been discussed in articles that have been published in the medical literature. All products containing FOSAMAX include the following language pertaining to ONJ in the "Precautions" section of their respective package circular: -- Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection, often with delayed healing, has been reported in patients taking bisphosphonates. Most reported cases of bisphosphonate-associated osteonecrosis have been in cancer patients treated with intravenous bisphosphonates, but some have occurred in patients with postmenopausal osteoporosis. Known risk factors for osteonecrosis include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), poor oral hygiene, and co-morbid disorders (e.g., preexisting dental disease, anemia, coagulopathy, infection). -- Patients who develop osteonecrosis of the jaw (ONJ) while on bisphosphonate therapy should receive care by an oral surgeon. Dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk for ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment. Information for ONJ is also provided in the "Adverse Reactions" section of the package circular as well as in the patient package insert for the products containing FOSAMAX. As part of a review of your medical history with your healthcare providers (such as dentists, physicians, oral surgeons or others), be sure to include any product containing FOSAMAX in your list of medicines and talk to your healthcare provider if you have any questions about FOSAMAX. FOSAMAX is indicated for the treatment of osteoporosis in postmenopausal women. For the treatment of osteoporosis, FOSAMAX increases bone mass and reduces the incidence of fracture, including those of the hip and spine. FOSAMAX is also indicated to increase bone mass in men with osteoporosis. Osteoporosis, the most prevalent bone disease in the U.S., can lead to bone loss and an increased risk of fractures. Over 10 million Americans over the age of 50 have osteoporosis and another 34 million have low bone mass. Osteoporosis is especially common in women after menopause, but also occurs in older men. Most often, it is due to an increase in the rate of resorption (breakdown) of bone tissue that is not matched by the rate of bone formation. The risk of having an osteoporosis-related fracture increases with age. According to the Surgeon General, osteoporosis is a national health threat and by 2020 one in two Americans over the age of 50 will be at risk for fractures from osteoporosis or low bone mass. In fact, one out of every two women over age 50 will have an osteoporosis-related fracture in their remaining lifetime, with the risk of fracture increasing with age. Important Information About FOSAMAX FOSAMAX, like other bisphosphonate containing products, should be used with caution in people with certain stomach or digestive problems. FOSAMAX should not be used if the patient has certain disorders of the esophagus that delay emptying or if the patient is unable to stand or sit upright for at least 30 minutes. In addition, FOSAMAX should not be used in patients with severe kidney disease or low levels of calcium in their blood, in patients who are allergic to FOSAMAX or in patients who are pregnant or nursing. Patients who have difficulty swallowing liquids should not take FOSAMAX oral solution. Some patients may develop severe digestive reactions including irritation, inflammation or ulceration of the esophagus. The risk of severe esophageal experiences appears to be greater in patients who fail to follow dosing instructions (see prescribing information for more details). Patients who experience new or worsening heartburn, difficulty or pain when swallowing or chest pain should stop taking the drug and call their doctor right away. Patients who develop severe bone, joint and/or muscle pain at any time should contact their doctor. The standard dosing regimen for FOSAMAX includes swallowing the tablet with six to eight ounces of plain water the first thing upon arising for the day and at least 30 minutes before the first food, beverage or medication of the day. After swallowing FOSAMAX, patients should not lie down for at least 30 minutes and not until after consuming their first food of the day. Patients should not chew or suck on a tablet of FOSAMAX. Merck


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009